The clade 1 case is the nation's first in a person with no recent travel history and the seventh clade 1 case in the country.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
Africa CDC also notes cholera surges in Chad, Burundi, and Angola, along with hopeful signs in the DR Congo's Ebola outbreak.
The vaccine campaign targeting almost 2 million people in Darfur region faces daunting access and transportation challenges amid ongoing conflict.
A larger proportion of patients with protracted cases were hospitalized than those with shorter infections (26% vs 5%).
Meanwhile, in cholera developments, the Africa CDC reports sharp rises in illnesses in Chad and the Republic of Congo.
Emergent BioSolutions has received a $56 million contract extension to supply the US government with doses of the ACAM2000 vaccine.
Meanwhile, Africa CDC extends its continental emergency declaration based on fragile progress, concerns about deaths, and the need to mobilize more resources.
Meanwhile, the US authorized the transfer of 219,000 vaccine doses, and the DR Congo deployed vaccine doses from Japan.
Cases and deaths have already outpaced totals for 2024, and new outbreaks have emerged in Gambia, Cameroon, and Mozambique.
The initiative is designed to accelerate testing, sequencing, capacity building, and local manufacturing for mpox and other priority pathogens.
Health officials facing depleted vaccine supplies are also tracking upticks in Nigeria, Liberia, Kenya, and Ghana, as well as in Togo and Mozambique.
